5. 团队
Asia Cell & Gene Therapeutics Group Due Diligent Data Room
5. Teams 团队
Celzyva Therapeutics, Inc. (Delaware, USA) 包括其全资美国子公司和香港子公司目前共计有全职员工12名。其中，博士4名、硕士6名、学士2名；研发人员11名、非研发人员1名。
Celzyva Therapeutics, Inc. (Delaware, USA) including its wholly-owned U.S. subsidiary and Hong Kong subsidiary currently have 12 full-time employees. The team comprises 4 PhDs, 6 with Master's degrees, and 2 with Bachelor's degrees. There are 11 R&D personnel and 1 non-R&D staff member.
5.1. 董事会 Board of Directors
5.2. 管理层 Management Team
| No. | Name | Photo | Position | Profile (中文 / Chinese) | Profile (English) |
|---|---|---|---|---|---|
| 1 | 齐念民 Hanshi Nianmin Qi (Jeff) |  | 董事长 / 首席财务官 Chairman of Board / CEO & CFO | 博士，教授。公司创始人，全面负责战略规划与运营管理。 | Ph.D., Professor. Founder of the company, overseeing overall strategy and operations. |
| 2 | 李宁 Ning Li |  | 首席技术官 CTO | 博士。专注于诱导多能干细胞（iPSC）的工艺开发与放大生产。 | Ph.D. Specializes in iPSC process development and scale-up manufacturing. |
| 4 | 赖思思 Sisi Lai | 首席科学官 CSO | 博士。负责？？？？？ | Ph.D. Responsible for MSC process optimization and quality control. |
| No. | Name | Photo | Position | Profile (中文 / Chinese) | Profile (English) |
|---|---|---|---|---|---|
| 1 | 纪猛 Ji Meng |  | 工艺和方法开发（科学家）Process & Analytical Development (Scientist) | 中国农业科学院硕士，专注于多能干细胞定向分化（视网膜色素上皮细胞、心肌细胞、NK细胞等）、CRISPR/Cas9基因编辑及CAR-T疗法研发。主导多个细胞治疗产品从概念到专利申报的全流程。 | M.S. in Genetic Engineering from Chinese Academy of Agricultural Sciences. Specializes in directed differentiation of pluripotent stem cells (RPE, cardiomyocytes, NK cells), CRISPR/Cas9 gene editing, and CAR-T therapy development. |
| 2 | 卢鹏 Lu Peng |  | 工艺和方法开发（科学家） Process & Analytical Development (Scientist) | 浙江理工大学生物学硕士。专注于多能干细胞（iPSC/ES）的2D/3D培养工艺开发，成功建立iPSC向NK细胞、巨噬细胞和心肌细胞的高效分化体系（NK纯度>95%），并实现3D悬浮放大培养及iNK扩增冻存工艺优化。 | M.S. in Biology from Zhejiang Sci-Tech University. Specializes in 2D/3D culture process development of pluripotent stem cells (iPSC/ES). Established high-efficiency differentiation protocols for iPSC-derived NK cells (>95% purity), macrophages, and cardiomyocytes, and optimized 3D suspension scale-up and iNK expansion/cryopreservation workflows. |
| 3 | MPhil in Cell and Molecular Biology from The Chinese University of Hong Kong. Expertise in neurodevelopment, mRNA localization, BMP signaling, and CSF extracellular vesicles. |
| No. | Name | Photo | Position | Profile (中文 / Chinese) | Profile (English) |
|---|---|---|---|---|---|
| 1 | 肖换茹 Ruth Xiao |  | 行政和商业支持 Administration & Business Support | 香港城市大学电子商务硕士，精通R、SAS、SQL及生物统计建模。 | MSc in Electronic Commerce from CityU HK. Proficient in R, SAS, SQL, and statistical modeling for biotech data. |
Company PersonnelAsia Cell & Gene Therapeutics Co., Ltd.(亚洲细胞与基因药物股份有限公司)的委托研发CRO-浙江泉生生物科技有限公司，包括其子公司，有全职员工共计35人。The contract research organization (CRO) engaged by Asia Cell & Gene Therapeutics Co., Ltd.—Zhejiang Quansheng Biotechnology Co., Ltd., including its subsidiaries—has a total of 25 full-time employees.